Wang, Belle Yu-Hsuan
Hsiao, Allen Wei-Ting
Shiu, Hoi Ting
Wong, Nicodemus
Wang, Amanda Yu-Fan
Lee, Chien-Wei
Lee, Oscar Kuang-Sheng
Lee, Wayne Yuk-Wai
Funding for this research was provided by:
Start-up grant from Chinese University of Hong Kong (Ref. Nos. 4930991, 4930992)
General Research Fund (Ref. Nos. 14120818, 14104620, 24121622)
Health and Medical Research Fund, The Food and Health Bureau (Ref. No. 06170546)
Partnership Research Programme, Innovation Technology Commission (Ref. No. PRP/090/20FX)
Area of Excellence, University Grants Committee (Ref. No. AoE/M-402/20)
Center for Neuromusculoskeletal Restorative Medicine, Health@InnoHK program, Innovation Technology Commission, Hong Kong SAR (Ref. No. CT1.1)
American Society for Bone and Mineral Research
National Science and Technology Council, Taiwan (111-2320-B-039-070-MY3)
Article History
Received: 13 February 2023
Accepted: 17 July 2023
First Online: 4 August 2023
Ethics approval and consent to participate
: The approved animal ethic by the Animal Experimentation Ethics Committee (AEEC) of The Chinese University of Hong Kong (Title: Therapeutic applications of exosomes from mesenchymal stem cells for sarcopenia; No.18/256/MIS-5-B; Date of approval: 10th, April, 2019) is proved in the Ethics approval session in the manuscript. All animal research followed the International Guiding Principles for Biomedical Research Involving Animals, ARRIVE guideline and The Hong Kong Code of Practice for Care and Use of Animals for Experimental Purposes.
: Not applicable.
: Oscar Kuang-Sheng Lee is a member of the editorial board of Stem Cell Research & Therapy, and he was not involved in the peer review, or decision-making of this article. All other authors declare that they have no competing interest.